PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28580075-4 2017 Low doses of AVP and its synthetic analog terlipressin can restore vasomotor tone in conditions that are resistant to catecholamines, with preservation of renal blood flow and urine output. Catecholamines 118-132 arginine vasopressin Homo sapiens 13-16 28144392-0 2017 Vasopressin use in critically ill cirrhosis patients with catecholamine-resistant septic shock: The CVICU cohort. Catecholamines 58-71 arginine vasopressin Homo sapiens 0-11 28144392-1 2017 AIM: To examine patient-centered outcomes with vasopressin (AVP) use in patients with cirrhosis with catecholamine-refractory septic shock. Catecholamines 101-114 arginine vasopressin Homo sapiens 47-58 26853286-1 2016 Arginine vasopressin as a supplementary vasopressor in septic shock restores vascular tone and mean arterial pressure, meanwhile decreases dose and exposure time to catecholamines. Catecholamines 165-179 arginine vasopressin Homo sapiens 9-20 24840762-9 2014 Our results suggest a potential role for vasopressin therapy in patients with CDH with catecholamine-resistant refractory hypotension. Catecholamines 87-100 arginine vasopressin Homo sapiens 41-52 26558621-6 2015 Thus, in recent years, interest in catecholamine-sparing agents such as vasopressin, terlipressin and methylene blue has increased; however, few randomized trials, mostly with small sample sizes, have been performed. Catecholamines 35-48 arginine vasopressin Homo sapiens 72-83 26689075-13 2015 Moreover, vasopressin may be utilized to treat catecholamine-resistant hypotension. Catecholamines 47-60 arginine vasopressin Homo sapiens 10-21 25541224-6 2015 However, under acidemic conditions and high catecholamine levels and/or absence of gasping, vasopressin should be administered instead. Catecholamines 44-57 arginine vasopressin Homo sapiens 92-103 25440643-14 2015 CONCLUSIONS: Vasopressin infusion has been used to treat catecholamine-unresponsive shock. Catecholamines 57-70 arginine vasopressin Homo sapiens 13-24 24747036-1 2014 PURPOSE: The objective of this study was to determine the effect of early vs late vasopressin therapy on catecholamine dose and duration. Catecholamines 105-118 arginine vasopressin Homo sapiens 82-93 24747036-3 2014 Patients were included in the early group if vasopressin was initiated within 6 hours and the late group if vasopressin was initiated between 6 and 48 hours of catecholamine(s). Catecholamines 160-173 arginine vasopressin Homo sapiens 108-119 24747036-5 2014 Vasopressin therapy was associated with a decrease in catecholamine requirements in both groups. Catecholamines 54-67 arginine vasopressin Homo sapiens 0-11 24228460-0 2013 [Low dose vasopressin is effective for catecholamine-resistant hypotension after resection of pheochromocytoma]. Catecholamines 39-52 arginine vasopressin Homo sapiens 10-21 23477980-3 2013 Vasopressin has also been studied on a limited basis for use in the treatment of catecholamine-resistant hypotension in vasodilatory shock. Catecholamines 81-94 arginine vasopressin Homo sapiens 0-11 23849528-2 2013 The postreperfusion syndrome has clearly defined and typically responds to vasopressin and/or methylene blue when refractory to catecholamine therapy. Catecholamines 128-141 arginine vasopressin Homo sapiens 75-86 23506497-10 2013 The first line vasopressor recommended at present is norepinephrine, while vasopressin can be started as a salvage therapy for those not responding to catecholamines. Catecholamines 151-165 arginine vasopressin Homo sapiens 75-86 23121213-4 2012 Low-dose vasopressin increases systemic blood pressure and decreases the need for catecholamines in brain-dead organ donors but it is not available in many countries. Catecholamines 82-96 arginine vasopressin Homo sapiens 9-20 23439212-1 2013 Vasopressin and its analogue terlipressin are potent vasopressors which have been recently proposed in the treatment of catecholamine-resistant septic shock. Catecholamines 120-133 arginine vasopressin Homo sapiens 0-11 23439212-5 2013 Nevertheless, low doses of vasopressin and terlipressin seem to have the potential to restore vasomotor tone in conditions refractory to catecholamines, improving organ perfusion with preservation of renal blood flow, while decreasing catecholamine requirements. Catecholamines 137-151 arginine vasopressin Homo sapiens 27-38 23439212-5 2013 Nevertheless, low doses of vasopressin and terlipressin seem to have the potential to restore vasomotor tone in conditions refractory to catecholamines, improving organ perfusion with preservation of renal blood flow, while decreasing catecholamine requirements. Catecholamines 137-150 arginine vasopressin Homo sapiens 27-38 23905079-1 2013 Arginine vasopressin (AVP) and its synthetic, long-acting analog terlipressin (TP) are potent alternative vasoconstrictors in the treatment of septic patients with catecholamine-refractive vasodilatatory shock. Catecholamines 164-177 arginine vasopressin Homo sapiens 9-20 22962322-16 2012 Intraoperative vasopressin infusion should not be used routinely, but only in catecholamine-refractory shock. Catecholamines 78-91 arginine vasopressin Homo sapiens 15-26 22508204-8 2012 We conclude that Infusion of low-dose vasopressin for patients with mild to moderate left ventricular systolic dysfunction during separation from CPB is beneficial for the postoperative hemodynamic profile, reduces the catecholamine doses required and improves left ventricular systolic function. Catecholamines 219-232 arginine vasopressin Homo sapiens 38-49 22889256-13 2012 CONCLUSIONS: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. Catecholamines 122-136 arginine vasopressin Homo sapiens 13-24 22361482-7 2012 Vasopressin has demonstrated utility in the management of catecholamine-resistant shock after tumor resection. Catecholamines 58-71 arginine vasopressin Homo sapiens 0-11 21855282-13 2012 CONCLUSIONS: Effects of vasopressin on catecholamine dosing requirements in the setting of septic shock may be influenced by body weight. Catecholamines 39-52 arginine vasopressin Homo sapiens 24-35 21926664-12 2012 CONCLUSION: Low-dose arginine vasopressin infusion initiated in the operating room after complex neonatal cardiac surgery was associated with decreased fluid resuscitation and catecholamine requirements in the first 24 postoperative hours. Catecholamines 176-189 arginine vasopressin Homo sapiens 30-41 22474806-5 2012 Following the case study is a discussion of the impact that angiotensin II inhibitors may have on a patient undergoing general anesthesia and the role of vasopressin in reversing catecholamine-resistant hypotension. Catecholamines 179-192 arginine vasopressin Homo sapiens 154-165 21922300-1 2012 OBJECTIVE: To assess the efficacy of arginine vasopressin (AVP) as a rescue therapy in children with catecholamine refractory vasodilatory shock and its effect on various hemodynamic, clinical, and laboratory variables. Catecholamines 101-114 arginine vasopressin Homo sapiens 46-57 21922300-11 2012 CONCLUSIONS: Concurrent addition of vasopressin at an appropriate stage help improving MAP significantly with decreased dependence on high dose catecholamines without any significant adverse effects. Catecholamines 144-158 arginine vasopressin Homo sapiens 36-47 21926888-1 2011 OBJECTIVE: : Vasopressin and its analog, terlipressin (TP), are potent vasopressors that may be useful therapeutic agents in the treatment of cardiac arrest (CA), septic and catecholamine-resistant shock, and esophageal variceal hemorrhage. Catecholamines 174-187 arginine vasopressin Homo sapiens 13-24 22762470-7 2012 Regarding catecholamine-resistant vasodilatory shock, current evidence suggests that with adequate volume resuscitation, exogenous vasopressin in low "physiologic" doses (0.01-0.04 units/min) safely supports mean arterial pressure without adversely affecting myocardial function and splanchnic circulation. Catecholamines 10-23 arginine vasopressin Homo sapiens 131-142 22762470-9 2012 Although there is yet no clear cut mortality benefit, vasopressin is now recommended as a second-line agent in septic shock for its catecholamine-sparing effect and as an alternative to epinephrine in cardiopulmonary resuscitation. Catecholamines 132-145 arginine vasopressin Homo sapiens 54-65 20874043-5 2010 Various studies have suggested that exogenous administration of arginine vasopressin may be an effective adjunctive therapy to traditional catecholamines for the management of hypotension during septic shock. Catecholamines 139-153 arginine vasopressin Homo sapiens 73-84 21253815-0 2011 The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature. Catecholamines 44-57 arginine vasopressin Homo sapiens 12-23 21377081-5 2011 Vasopressin, a catecholamine-sparing vasopressor and antidiuretic agent, may be an effective agent in the treatment of refractory hypotension after brain death prior to organ transplantation. Catecholamines 15-28 arginine vasopressin Homo sapiens 0-11 20498605-0 2010 Vasopressin for the treatment of catecholamine-resistant hypotension during a phaeochromocytoma resection in a 6-year-old child. Catecholamines 33-46 arginine vasopressin Homo sapiens 0-11 20838244-1 2010 The purpose of this study was to determine whether the increased expression of tyrosine hydroxylase (TH), the first and limiting enzyme in catecholamine synthesis in vasopressin (VP) neurons of the human neonate, represents a primary developmental phenomenon or reflects a secondary phenomenon related to the activation of VP systems due to perinatal hypoxia. Catecholamines 139-152 arginine vasopressin Homo sapiens 166-177 20935620-1 2010 Arginine vasopressin (AVP) and its synthetic, long-acting analog terlipressin (TP) are potent alternative vasoconstrictors in the treatment of septic patients with catecholamine-refractive vasodilatatory shock. Catecholamines 164-177 arginine vasopressin Homo sapiens 9-20 19793209-14 2010 CONCLUSIONS: Low-dose AVP therapy should be considered as rescue therapy when high-dose catecholamine therapy and/or steroid administration do not produce sufficient increase in the blood pressure. Catecholamines 88-101 arginine vasopressin Homo sapiens 22-25 20727442-1 2010 Intravenous vasopressin at 0.01 to 0.04 units/kg/h increased median mean blood pressure from 26 mm Hg (range 18-44) to 41 mm Hg (range 17-90) by 12 hours of infusion (P=.002) and allowed weaning of catecholamines in a group of extremely low birth weight infants with refractory hypotension. Catecholamines 198-212 arginine vasopressin Homo sapiens 12-23 19999914-3 2009 Vasopressin has emerged as a possible pharmacologic adjunct, particularly in patients with shock refractory to the administration of fluids and catecholamines. Catecholamines 144-158 arginine vasopressin Homo sapiens 0-11 20346182-13 2010 Vasopressin administration (for group A) was associated with a higher 24 hour diuresis) (0.0001).In conclusion, low-dose of infused vasopressin during cardiopulmonary bypass and for the next 4 hours is beneficial for its postoperative hemodynamic profile, reduces the doses of requirements of catecholamines and contributes to prevention of the postcardiotomy vasoplegic shock in the patient with low ejection fraction who is receiving ACE preoperatively. Catecholamines 293-307 arginine vasopressin Homo sapiens 0-11 20346182-13 2010 Vasopressin administration (for group A) was associated with a higher 24 hour diuresis) (0.0001).In conclusion, low-dose of infused vasopressin during cardiopulmonary bypass and for the next 4 hours is beneficial for its postoperative hemodynamic profile, reduces the doses of requirements of catecholamines and contributes to prevention of the postcardiotomy vasoplegic shock in the patient with low ejection fraction who is receiving ACE preoperatively. Catecholamines 293-307 arginine vasopressin Homo sapiens 132-143 19691565-9 2009 CONCLUSION: Vasopressin (0.01-0.04 U/min, IV) should be considered in small animal veterinary patients with vasodilatory shock that is unresponsive to fluid resuscitation and catecholamine (dobutamine, dopamine, and norepinephrine) administration. Catecholamines 175-188 arginine vasopressin Homo sapiens 12-23 19640370-0 2009 The long-term survival rate of catecholamine-resistant septic shock in Japanese patients who received vasopressin therapy. Catecholamines 31-44 arginine vasopressin Homo sapiens 102-113 19640370-3 2009 METHODS: 55 Japanese patients experiencing catecholamine-resistant septic shock were treated with vasopressin. Catecholamines 43-56 arginine vasopressin Homo sapiens 98-109 19640370-9 2009 CONCLUSIONS: In Japanese septic shock patients, vasopressin infusion improved hemodynamic status and reduced catecholamine requirement, and 28-day survival rate was 45%. Catecholamines 109-122 arginine vasopressin Homo sapiens 48-59 19572935-1 2009 BACKGROUND: The beneficial effects of vasopressin on diuresis and creatinine clearance have been demonstrated when used as an additional/alternative therapy in catecholamine-dependent vasodilatory shock. Catecholamines 160-173 arginine vasopressin Homo sapiens 38-49 30625797-6 2009 This report describes our experience of the anesthetic management for the removal of pheochromocytoma with catecholamine-induced cardiomyopathy, which barely responded to high vasopressin and epinephrine. Catecholamines 107-120 arginine vasopressin Homo sapiens 176-187 18496412-7 2008 Observational studies have reported an improvement in blood pressure and rapid weaning off catecholamines during administration of low-dose vasopressin. Catecholamines 91-105 arginine vasopressin Homo sapiens 140-151 19049483-0 2008 Monitoring of brain tissue oxygen tension and use of vasopressin after cardiac arrest in a child with catecholamine-induced cardiac arrhythmia. Catecholamines 102-115 arginine vasopressin Homo sapiens 53-64 18670203-9 2008 Decreased circulating vasopressin contributes to adrenal insufficiency via hypothalamic-pituitary-adrenal axis suppression and increased catecholamine resistance to vasopressors. Catecholamines 137-150 arginine vasopressin Homo sapiens 22-33 19664189-1 2009 During advanced vasodilatory shock, arginine vasopressin (AVP) is increasingly used to restore blood pressure and thus to reduce catecholamine requirements. Catecholamines 129-142 arginine vasopressin Homo sapiens 45-56 27688562-0 2008 Effects of Low Dose Vasopressin in Catecholamine Resistant Septic Shock. Catecholamines 35-48 arginine vasopressin Homo sapiens 20-31 27688562-12 2008 CONCLUSION: Low dose vasopressin at the rate of 0.04 unit/minute is an effective vasopressor in adult patients with catecholamine resistant septic shock. Catecholamines 116-129 arginine vasopressin Homo sapiens 21-32 18687199-1 2008 Arginine vasopressin and terlipressin increase mean arterial pressure and reduce catecholamine requirements in septic shock patients. Catecholamines 81-94 arginine vasopressin Homo sapiens 9-20 18830525-0 2008 Vasopressin for the management of catecholamine-resistant anaphylactic shock. Catecholamines 34-47 arginine vasopressin Homo sapiens 0-11 18434255-5 2008 These results demonstrate that this catecholamine may inhibit vasopressin-stimulated water transport at a site prior to cAMP formation. Catecholamines 36-49 arginine vasopressin Homo sapiens 62-73 18683481-1 2008 The synthetic vasopressin analogue, terlipressin, is being increasingly used to treat catecholamine-resistant hypotension in septic shock and other conditions. Catecholamines 86-99 arginine vasopressin Homo sapiens 14-25 18683484-1 2008 Vasopressin analogues are increasingly used for haemodynamic support of catecholamine-refractory, hyperdynamic septic shock. Catecholamines 72-85 arginine vasopressin Homo sapiens 0-11 18683484-2 2008 Arginine vasopressin (AVP) and terlipressin (TP) effectively increase mean arterial pressure and reduce catecholamine requirements in this condition. Catecholamines 104-117 arginine vasopressin Homo sapiens 9-20 18052900-5 2007 Three higher-quality studies of catecholamines (noradrenaline, adrenaline, dopamine and vasopressin) have been completed, the results of which will provide some evidence of efficacy of catecholamines on mortality and resolution of shock. Catecholamines 185-199 arginine vasopressin Homo sapiens 88-99 18081903-0 2008 Vasopressin in catecholamine-refractory shock in children. Catecholamines 15-28 arginine vasopressin Homo sapiens 0-11 17431678-0 2008 Arginine-vasopressin as a rescue therapy in children and neonates for catecholamine-resistant shock. Catecholamines 70-83 arginine vasopressin Homo sapiens 9-20 18431272-13 2008 CONCLUSIONS: Some catecholamines can induce an inflammatory response and exacerbate the hepatic dysfunction observed during sepsis, favoring the idea that catecholamines could alter the biotransformation of drugs metabolized by CYP3A4 and that alternative vasoactive agents, such as vasopressin, merit further investigation in septic shock patients. Catecholamines 18-32 arginine vasopressin Homo sapiens 283-294 18431272-13 2008 CONCLUSIONS: Some catecholamines can induce an inflammatory response and exacerbate the hepatic dysfunction observed during sepsis, favoring the idea that catecholamines could alter the biotransformation of drugs metabolized by CYP3A4 and that alternative vasoactive agents, such as vasopressin, merit further investigation in septic shock patients. Catecholamines 155-169 arginine vasopressin Homo sapiens 283-294 17413940-0 2007 Use of vasopressin bolus and infusion to treat catecholamine-resistant hypotension during pheochromocytoma resection. Catecholamines 47-60 arginine vasopressin Homo sapiens 7-18 17599006-3 2007 RECENT FINDINGS: Examples of types of shock resistant to catecholamine pressors in which exogenous vasopressin was effective in restoring arterial pressure continued to accumulate. Catecholamines 57-70 arginine vasopressin Homo sapiens 99-110 17599007-3 2007 The vasoactive properties of vasopressin have been more applicable clinically because of the discovery by Landry and colleagues that there is a deficiency of vasopressin in septic shock and that infusion of relatively low doses of vasopressin improves responsiveness to infused catecholamines (such as norepinephrine). Catecholamines 278-292 arginine vasopressin Homo sapiens 29-40 17594065-6 2007 The hemodynamic effects of AVP were comparable to those AVP-induced alterations described in septic shock and seem to be predominantly mediated by potent vasoconstriction and the facilitated reduction of higher, potentially toxic catecholamine doses. Catecholamines 230-243 arginine vasopressin Homo sapiens 27-30 17624234-2 2007 In septic adults, vasopressin-terlipressin have been shown to increase mean arterial pressure and to decrease the necessity for catecholamines. Catecholamines 128-142 arginine vasopressin Homo sapiens 18-29 17319503-7 2007 There are an increasing number of reports that indicate that vasopressin is effective for distributive shock, especially catecholamine-resistant septic shock. Catecholamines 121-134 arginine vasopressin Homo sapiens 61-72 17265038-2 2007 In the irreversible phase of hemorrhagic shock that was unresponsive to volume replacement, airway management and catecholamines, vasopressin was beneficial due to an increase in arterial blood pressure, shift of blood away from a subdiaphragmatic bleeding site towards the heart and brain and decrease of fluid resuscitation requirements. Catecholamines 114-128 arginine vasopressin Homo sapiens 130-141 17356185-2 2007 Arginine vasopressin (AVP) has been shown to stabilize advanced shock states while facilitating reduction of catecholamine doses, but its use has never been reported in SAH. Catecholamines 109-122 arginine vasopressin Homo sapiens 0-20 17356185-2 2007 Arginine vasopressin (AVP) has been shown to stabilize advanced shock states while facilitating reduction of catecholamine doses, but its use has never been reported in SAH. Catecholamines 109-122 arginine vasopressin Homo sapiens 22-25 18265860-1 2007 BACKGROUND AND AIMS: Arginin vasopressin (AVP) is a potent vasoconstrictor which has been used in vasodilatory shock when therapy with catecholamines and fluids has failed. Catecholamines 135-149 arginine vasopressin Homo sapiens 21-40 18265860-1 2007 BACKGROUND AND AIMS: Arginin vasopressin (AVP) is a potent vasoconstrictor which has been used in vasodilatory shock when therapy with catecholamines and fluids has failed. Catecholamines 135-149 arginine vasopressin Homo sapiens 42-45 16909734-4 2006 Infusion of vasopressin (VP) which is detectable at inappropriately low level in advanced phase of septic shock might allow withdrawal of catecholamines, as it maintains adequate mean arterial pressure (MAP), improves urine output and leaves perfusion of vital organs unhindered. Catecholamines 138-152 arginine vasopressin Homo sapiens 12-23 17123948-0 2006 Role of exogenous arginine vasopressin in the management of catecholamine-refractory septic shock. Catecholamines 60-73 arginine vasopressin Homo sapiens 27-38 17076765-4 2006 Although the mechanism of the stress-mediated vasopressin release is not entirely understood, it is generally accepted that catecholamines play a crucial role in influencing water balance by modulating the secretion of vasopressin. Catecholamines 124-138 arginine vasopressin Homo sapiens 219-230 16982509-0 2006 Vasopressin in catecholamine-resistant septic and cardiogenic shock in very-low-birthweight infants. Catecholamines 15-28 arginine vasopressin Homo sapiens 0-11 16982509-1 2006 AIM: To evaluate vasopressin as a rescue therapy in catecholamine-refractory septic and cardiogenic shock in very-low-birthweight (VLBW) infants. Catecholamines 52-65 arginine vasopressin Homo sapiens 17-28 16982509-2 2006 METHODS: Prospective assessment of vasopressin therapy in three VLBW infants with catecholamine-refractory septic shock (24 + 6 wk, 600 g) and cardiogenic shock (26 + 1 wk, 890 g; 26 + 1 wk, 880 g) at a university hospital. Catecholamines 82-95 arginine vasopressin Homo sapiens 35-46 16982509-4 2006 CONCLUSION: Although vasopressin appears to be a suitable rescue therapy in catecholamine-resistant septic shock in VLBW infants, further evaluation in controlled clinical trials is warranted. Catecholamines 76-89 arginine vasopressin Homo sapiens 21-32 16931995-4 2006 Infusion of vasopressin (0.01-0.04 U/min) decreases catecholamine requirements in patients with sepsis and other types of vasodilatory shock. Catecholamines 52-65 arginine vasopressin Homo sapiens 12-23 17151983-4 2006 In such advanced, catecholamine-resistant shock states, arginine-vasopressin (AVP) has repeatedly caused an increase in mean arterial blood pressure, a decrease in toxic norepinephrine-dosages, as well as further beneficial hemodynamic, endocrinologic and renal effects. Catecholamines 18-31 arginine vasopressin Homo sapiens 65-76 16909734-4 2006 Infusion of vasopressin (VP) which is detectable at inappropriately low level in advanced phase of septic shock might allow withdrawal of catecholamines, as it maintains adequate mean arterial pressure (MAP), improves urine output and leaves perfusion of vital organs unhindered. Catecholamines 138-152 arginine vasopressin Homo sapiens 25-27 16505698-0 2006 Peripheral administration of vasopressin for catecholamine-resistant hypotension complicated by skin necrosis. Catecholamines 45-58 arginine vasopressin Homo sapiens 29-40 16575349-2 2006 Initial evaluations have shown that vasopressin may have a role in catecholamine refractory shock in adults. Catecholamines 67-80 arginine vasopressin Homo sapiens 36-47 17135716-1 2006 Tyrosine hydroxylase (TH), the first and limiting enzyme for catecholamine synthesis, has been identified immunohistochemically (IHC) in human neurosecretory neurons where it is found to colocalize with vasopressin (AVP) or oxytocin. Catecholamines 61-74 arginine vasopressin Homo sapiens 203-214 16489848-12 2006 In the clinical setting, we observed positive effects of vasopressin in some patients with life-threatening hemorrhagic shock, which had no longer responded to adrenergic catecholamines and fluid resuscitation. Catecholamines 171-185 arginine vasopressin Homo sapiens 57-68 16542483-4 2006 Beneficial effects of adding vasopressin were observed in other catecholamine-refractory shock states as well, such as vasodilatory shock and haemorrhagic shock. Catecholamines 64-77 arginine vasopressin Homo sapiens 29-40 16677425-0 2006 Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury. Catecholamines 24-37 arginine vasopressin Homo sapiens 9-20 16677425-1 2006 INTRODUCTION: The aim of this study was to assess the efficacy of arginine-vasopressin (AVP) as a rescue therapy in catecholamine-refractory septic and non-septic shock in extremely low birth weight (ELBW) infants with acute renal injury. Catecholamines 116-129 arginine vasopressin Homo sapiens 66-86 16677425-1 2006 INTRODUCTION: The aim of this study was to assess the efficacy of arginine-vasopressin (AVP) as a rescue therapy in catecholamine-refractory septic and non-septic shock in extremely low birth weight (ELBW) infants with acute renal injury. Catecholamines 116-129 arginine vasopressin Homo sapiens 88-91 16677425-4 2006 RESULTS: In all three ELBW infants with catecholamine-resistant septic shock, systemic arterial blood pressure increased substantively with restoration of urine output after AVP administration (dosage, 0.035 to 0.36 U/kg/h; length, 70 +/- 21 hours). Catecholamines 40-53 arginine vasopressin Homo sapiens 174-177 16677425-7 2006 CONCLUSION: AVP may be a promising rescue therapy in catecholamine-resistant shock in ELBW infants with acute renal injury. Catecholamines 53-66 arginine vasopressin Homo sapiens 12-15 16696866-10 2006 This observation may partly explain why AVP is such a potent vasopressor hormone and can increase systemic vascular resistance even in advanced vasodilatory shock unresponsive to increases in standard catecholamine therapy. Catecholamines 201-214 arginine vasopressin Homo sapiens 40-43 17319465-8 2006 Replacement doses of hydrocortisone and vasopressin may reduce mortality and improve hypotension, respectively, in a subgroup of patients with catecholamine-refractory septic shock. Catecholamines 143-156 arginine vasopressin Homo sapiens 40-51 16028663-0 2005 Vasopressin infusion in children with catecholamine-resistant septic shock. Catecholamines 38-51 arginine vasopressin Homo sapiens 0-11 16255662-2 2005 Vasopressin infusions are currently used as rescue therapy for the treatment of vasodilatory, catecholamine-resistant septic shock. Catecholamines 94-107 arginine vasopressin Homo sapiens 0-11 16146482-0 2005 Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Catecholamines 104-117 arginine vasopressin Homo sapiens 52-63 16116000-2 2005 Both patients responded to a small-dose infusion of vasopressin, which allowed tapering off of the catecholamines. Catecholamines 99-113 arginine vasopressin Homo sapiens 52-63 16116000-3 2005 The possible role of small-dose infusions of vasopressin in fluid- and catecholamine-resistant hemorrhagic shock is discussed. Catecholamines 71-84 arginine vasopressin Homo sapiens 45-56 15605286-4 2005 In this case report, we present two cases with temporarily successful cardiopulmonary resuscitation (CPR) using vasopressin and catecholamines in uncontrolled hemorrhagic shock with subsequent cardiac arrest that was refractory to catecholamines and fluid replacement. Catecholamines 231-245 arginine vasopressin Homo sapiens 112-123 16001320-7 2005 Overall, the sometimes desperate clinical situation has led to a large number of case reports und uncontrolled series of retrospectively analysed cases, where vasopressin or methylenblue were discribed as successfully reversing catecholamine resistent hypotension. Catecholamines 228-241 arginine vasopressin Homo sapiens 159-170 16028663-1 2005 AIM: To describe use of vasopressin infusion for catecholamine-refractory septic shock in children. Catecholamines 49-62 arginine vasopressin Homo sapiens 24-35 16028663-5 2005 CONCLUSIONS: Vasopressin appears to be useful in treatment of catecholamine-refractory septic shock in children. Catecholamines 62-75 arginine vasopressin Homo sapiens 13-24 15875138-2 2005 VP was infused in two posthemorrhagic vasodilatory shock patients when they remained persistently hypotensive despite adequate fluid resuscitation and infusions of pharmacological doses of catecholamines. Catecholamines 189-203 arginine vasopressin Homo sapiens 0-2 15178740-15 2004 In the meantime, vasopressin infusion at <or=0.03 units/min should be considered only if response to 1 or 2 catecholamine vasopressors is inadequate or as a method to reduce the dose of these therapies. Catecholamines 111-124 arginine vasopressin Homo sapiens 17-28 15448539-0 2004 Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. Catecholamines 38-51 arginine vasopressin Homo sapiens 0-11 15488059-1 2004 Vasopressin and its analogue, terlipressin, are potent vasopressors that may be useful therapeutic agents in the treatment of cardiac arrest, septic and catecholamine-resistant shock and oesophageal variceal haemorrhage. Catecholamines 153-166 arginine vasopressin Homo sapiens 0-11 15488059-5 2004 Low doses of vasopressin and terlipressin can restore vasomotor tone in conditions that are resistant to catecholamines, with preservation of renal blood flow and urine output. Catecholamines 105-119 arginine vasopressin Homo sapiens 13-24 15315626-1 2004 Terlipressin--a long-acting analogue of vasopressin--has been described to restore blood pressure in patients with catecholamine-resistant septic shock without obvious complications. Catecholamines 115-128 arginine vasopressin Homo sapiens 40-51 15281498-5 2004 An IV infusion of vasopressin was given to prevent systemic hypotension resulting from sympathetic blockade while avoiding increases in pulmonary vascular resistance that may have resulted from catecholamine usage. Catecholamines 194-207 arginine vasopressin Homo sapiens 18-29 15305765-18 2004 In shock states with the deficit of endogenous vasopressin, which are resistant to high doses of catecholamines, administration of vasopressin analogues represents a new perspective therapy. Catecholamines 97-111 arginine vasopressin Homo sapiens 47-58 15103461-5 2004 However, vasopressin causes arterial smooth muscle cell contraction through a non-catecholamine receptor pathway, thus it represents an attractive adjunct to the management of septic shock, especially when catecholamines are ineffective. Catecholamines 206-220 arginine vasopressin Homo sapiens 9-20 15305765-18 2004 In shock states with the deficit of endogenous vasopressin, which are resistant to high doses of catecholamines, administration of vasopressin analogues represents a new perspective therapy. Catecholamines 97-111 arginine vasopressin Homo sapiens 131-142 14562217-0 2003 [Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent]. Catecholamines 77-90 arginine vasopressin Homo sapiens 1-12 14562217-6 2003 CONCLUSION: In circulatory shock due to toxic vasodilatation the use of vasopressin analogue argipressin can be helpful as an ultima therapeutic measure in catecholamine refractory shock caused by vasodilatation. Catecholamines 156-169 arginine vasopressin Homo sapiens 72-83 12873956-0 2003 Early use of small-dose vasopressin for unstable hemodynamics in an acute brain injury patient refractory to catecholamine treatment: a case report. Catecholamines 109-122 arginine vasopressin Homo sapiens 24-35 12645718-3 2003 In patients receiving ACE inhibition, we investigated whether initiation of vasopressin before CPB would diminish post-CPB hypotension and catecholamine use by avoiding vasopressin deficiency. Catecholamines 139-152 arginine vasopressin Homo sapiens 76-87 12732600-3 2003 Arginine vasopressin (AVP) has recently been shown to be a potent vasopressor agent to stabilize cardiocirculatory function even in patients with catecholamine-resistant vasodilatory shock. Catecholamines 146-159 arginine vasopressin Homo sapiens 9-20 17021455-3 2003 RECENT FINDINGS: Several retrospective investigations give evidence that vasopressin at a dosage of 2-6 U/h is effective in reversing catecholamine-resistant vasodilatory shock due to sepsis or after cardiopulmonary bypass, but prospective randomized controlled trials are warranted. Catecholamines 134-147 arginine vasopressin Homo sapiens 73-84 12771608-0 2003 Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Catecholamines 78-91 arginine vasopressin Homo sapiens 54-65 12645718-6 2003 After CPB, the vasopressin group had a lower peak norepinephrine dose than the placebo group (4.6 +/- 2.5 versus 7.3 +/- 3.5 microg/min, p = 0.03), a shorter period on catecholamines (5 +/- 6 versus 11 +/- 7 hours, p = 0.03), fewer hypotensive episodes (1 +/- 1 versus 4 +/- 2, p < 0.01), and a shorter intensive care unit length of stay (1.2 +/- 0.4 versus 2.1 +/- 1.4 days, p = 0.03). Catecholamines 168-182 arginine vasopressin Homo sapiens 15-26 12180588-0 2002 The use of vasopressin to treat catecholamine-resistant hypotension after phaeochromocytoma removal. Catecholamines 32-45 arginine vasopressin Homo sapiens 11-22 12534330-3 2003 We report on physiological and pharmacological aspects of arginine vasopressin, and summarise current clinical knowledge on employing a continuous arginine vasopressin infusion in critically ill patients with catecholamine-resistant vasodilatory shock of different aetiologies. Catecholamines 209-222 arginine vasopressin Homo sapiens 156-167 12534330-5 2003 Because data on adverse effects are still limited, arginine vasopressin should be reserved for patients in whom adequate haemodynamic stabilisation cannot be achieved with conventional vasopressor therapy or who have obvious adverse effects of catecholamines that result in further significant haemodynamic deterioration. Catecholamines 244-258 arginine vasopressin Homo sapiens 60-71 12538968-2 2002 There are, in the literature, several cases of septic shock refractory to high-dose catecholamines successfully treated with arginine-vasopressin, a selective V1 agonist. Catecholamines 84-98 arginine vasopressin Homo sapiens 134-145 12391525-3 2002 Recent studies have shown that arginine vasopressin, an endogenous hormone of the neurohypophysis, may be a potent vasopressor when used in combination with catecholamines. Catecholamines 157-171 arginine vasopressin Homo sapiens 40-51 12391525-4 2002 During catecholamine-resistant septic and postcardiotomy shock, argine vasopressin results in a significant increase in mean arterial pressure as well as a significant decrease in heart rate and vasopressor requirements. Catecholamines 7-20 arginine vasopressin Homo sapiens 71-82 12180588-4 2002 The experience with this case suggests that vasopressin may be a useful adjunct in the treatment of catecholamine-resistant hypotension after phaeochromocytoma excision. Catecholamines 100-113 arginine vasopressin Homo sapiens 44-55 12163813-1 2002 OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock. Catecholamines 149-162 arginine vasopressin Homo sapiens 119-130 12107681-1 2002 OBJECTIVE: Arginine-vasopressin (AVP) might be a potent vasopressor agent in catecholamine-resistant postcardiotomy shock. Catecholamines 77-90 arginine vasopressin Homo sapiens 20-31 11476743-9 2001 When adrenergic vasopressors were unable to maintain arterial blood pressure in patients with vasodilatory shock, continuous infusions of vasopressin ( approximately 0.04 to approximately 0.1 U/min) stabilised cardiocirculatory parameters, and even ensured weaning from catecholamines. Catecholamines 270-284 arginine vasopressin Homo sapiens 138-149 11810719-10 2002 Namely, glucocorticoids, VP, catecholamines, glutamate, and opioids provide short-term or long-lasting effects on differentiating VP neurons. Catecholamines 29-43 arginine vasopressin Homo sapiens 130-132 11436522-6 2001 When adrenergic vasopressors were unable to maintain arterial blood pressure in patients with vasodilatory shock, continuous infusions of vasopressin (0.04-0.10 U/min) stabilized cardiocirculatory parameters and even ensured weaning from catecholamines. Catecholamines 238-252 arginine vasopressin Homo sapiens 138-149 11511958-13 2001 CONCLUSIONS: In this group of patients with severe septic shock, vasopressin infusion increased MAP and urine output and decreased catecholamine requirements. Catecholamines 131-144 arginine vasopressin Homo sapiens 65-76 11429329-0 2001 The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Catecholamines 55-68 arginine vasopressin Homo sapiens 15-26 10667533-8 2000 MEASUREMENTS AND MAIN RESULTS: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90+/-4.7 to 130+/-2.3 mm Hg while reducing the administration of catecholamine pressors. Catecholamines 172-185 arginine vasopressin Homo sapiens 31-42 11373409-1 2001 OBJECTIVE: To investigate the physiologic effects of exogenous vasopressin as a potential alternative to traditional high-dose catecholamine therapy for septic patients with vascular hyporeactivity to catecholamines. Catecholamines 201-215 arginine vasopressin Homo sapiens 63-74 11373409-4 2001 PATIENTS: Vasopressin was infused in 16 critically ill septic patients who remained persistently hypotensive despite infusions of pharmacologic doses of catecholamines. Catecholamines 153-167 arginine vasopressin Homo sapiens 10-21 11373409-13 2001 CONCLUSIONS: Low-dose vasopressin infusions increased mean arterial pressure, systemic vascular resistance, and urine output in patients with vasodilatory septic shock and hyporesponsiveness to catecholamines. Catecholamines 194-208 arginine vasopressin Homo sapiens 22-33 11102496-1 2000 The A1 catecholamine neurons of the caudal ventrolateral medulla transmit hemodynamic information to the vasopressin (VP) neurons in the hypothalamus. Catecholamines 7-20 arginine vasopressin Homo sapiens 105-116 11102496-1 2000 The A1 catecholamine neurons of the caudal ventrolateral medulla transmit hemodynamic information to the vasopressin (VP) neurons in the hypothalamus. Catecholamines 7-20 arginine vasopressin Homo sapiens 118-120 10853217-0 2000 Vasopressin effective in reversing catecholamine-resistant vasodilatory shock. Catecholamines 35-48 arginine vasopressin Homo sapiens 0-11 10853217-4 2000 The experience with this case suggests that vasopressin may be a valuable adjunct to the treatment of catecholamine-resistant vasodilatory shock. Catecholamines 102-115 arginine vasopressin Homo sapiens 44-55 11488255-34 2001 AVP might be responsible for an increased catecholamine activity. Catecholamines 42-55 arginine vasopressin Homo sapiens 0-3 11310526-2 2001 Addition of vasopressin helped reduce standard catecholamine need while maintaining adequate arterial blood pressure. Catecholamines 47-60 arginine vasopressin Homo sapiens 12-23 34381743-2 2021 Arginine vasopressin has gained popularity in recent years as a non-catecholamine vasoactive medication due to its unique properties. Catecholamines 68-81 arginine vasopressin Homo sapiens 9-20 10567311-9 1999 In these patients, low-dose vasopressin significantly increases blood pressure with a pressor response sufficient to reduce catecholamine administration. Catecholamines 124-137 arginine vasopressin Homo sapiens 28-39 9832689-14 1998 In patients exhibiting this syndrome after high-risk cardiac operations, replacement of arginine vasopressin increases blood pressure and reduces catecholamine pressor requirements. Catecholamines 146-159 arginine vasopressin Homo sapiens 97-108 8190253-1 1994 Noxious somatic stimuli elicit vasopressin secretion, an effect thought to result from activation of a facilitatory input from A1 catecholamine cells of the medulla oblongata. Catecholamines 130-143 arginine vasopressin Homo sapiens 31-42 1972647-3 1990 A neuromodulatory interaction that has been linked to memory function and which has been the subject of biochemical inquiry is the interaction between the catecholamine, norepinephrine (NE) and the neuropeptide, vasopressin (AVP). Catecholamines 155-168 arginine vasopressin Homo sapiens 212-223 2153488-6 1990 An arginine vasopressin level of 18 X 10(12) mol/l, which can be achieved physiologically, increased the sensitivity of platelets to adenosine 5"-pyrophosphate and collagen in vitro; the same concentration of arginine vasopressin caused a potentiation of the effect of catecholamines on the response of platelets to sodium arachidonate. Catecholamines 269-283 arginine vasopressin Homo sapiens 12-23 33034000-0 2021 Utility of Low Dose Vasopressin for Persistent Pulmonary Hypertension of Newborn with Catecholamine Refractory Shock. Catecholamines 86-99 arginine vasopressin Homo sapiens 20-31 33034000-1 2021 OBJECTIVE: To evaluate the effect of low dose vasopressin on the hemodynamics of neonates with persistent pulmonary hypertension and catecholamine refractory shock. Catecholamines 133-146 arginine vasopressin Homo sapiens 46-57 10528604-10 1999 CONCLUSION: A VP infusion improved arterial pressure and permitted the withdrawal of catecholamine vasopressors. Catecholamines 85-98 arginine vasopressin Homo sapiens 14-16 9054839-6 1997 Although vasopressin is a weak pressor in normal subjects, its administration at 0.04 U/min to 10 patients with septic shock who were receiving catecholamines increased arterial pressure (systolic/diastolic) from 92/52 to 146/66 mm Hg (P < .001/P < .05) due to peripheral vasoconstriction (systemic vascular resistance increased from 644 to 1187 dyne.s/cm5; P < .001). Catecholamines 144-158 arginine vasopressin Homo sapiens 9-20 8454456-2 1993 Activation of these multiple systems--as a result of renin, angiotensin II and the action of circulatory catecholamines--causes the release of norepinephrine vasopressin and aldosterone. Catecholamines 105-119 arginine vasopressin Homo sapiens 158-169 2046887-0 1991 Neural modulation of lysine vasopressin-induced changes of catecholamines in the adrenal medulla of the pigeon. Catecholamines 59-73 arginine vasopressin Homo sapiens 28-39 34367696-2 2021 The purpose of this study was to evaluate the relationship between the plasma levels of catecholamines (such as epinephrine (Ep), norepinephrine (Nep), and dopamine) and vasopressin (antidiuretic hormone (ADH)) and the acquisition of return of spontaneous circulation (ROSC) in OHCA patients. Catecholamines 88-102 arginine vasopressin Homo sapiens 183-203 2935570-18 1985 Vasopressin"s central actions on the cardiovascular medullary centres, the baroreflex, the autonomic nervous system and catecholamine metabolism may also be involved in some hypertensive processes. Catecholamines 120-133 arginine vasopressin Homo sapiens 0-11 35195486-0 2022 Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically ill Patients with Septic Shock. Catecholamines 24-37 arginine vasopressin Homo sapiens 54-65 35195486-2 2022 Methods: This multicenter retrospective cohort study conducted in critically ill adults sought to evaluate the role of catecholamine requirements and timing on responsiveness to AVP. Catecholamines 119-132 arginine vasopressin Homo sapiens 178-181 35156051-6 2022 PATIENTS: Patients with septic shock initiated on vasopressin as a catecholamine adjunct between January 2012 and November 2017 were screened for inclusion. Catecholamines 67-80 arginine vasopressin Homo sapiens 50-61 35156051-11 2022 For each 0.1 unit the pH was below 7.40 at vasopressin initiation, the norepinephrine-equivalent catecholamine dose increased by 1.5 microg/min (95% CI, 0.5-2.5 microg/min) at 1 hour, and increased by 2.5 microg/min (95% CI, 1.4-3.5 microg/min) at 6 hours after vasopressin initiation. Catecholamines 97-110 arginine vasopressin Homo sapiens 43-54 35156051-11 2022 For each 0.1 unit the pH was below 7.40 at vasopressin initiation, the norepinephrine-equivalent catecholamine dose increased by 1.5 microg/min (95% CI, 0.5-2.5 microg/min) at 1 hour, and increased by 2.5 microg/min (95% CI, 1.4-3.5 microg/min) at 6 hours after vasopressin initiation. Catecholamines 97-110 arginine vasopressin Homo sapiens 262-273 35156051-12 2022 CONCLUSIONS: Compared with higher arterial pH, patients with septic shock and low arterial pH had lower odds of vasopressin response and higher catecholamine doses after vasopressin initiation. Catecholamines 144-157 arginine vasopressin Homo sapiens 170-181 3138577-0 1988 Differential effects of hypothalamic catecholamine depletion on the release of arginine vasopressin and CRF-41 into hypothalamo-hypophyseal portal blood. Catecholamines 37-50 arginine vasopressin Homo sapiens 88-99 3304733-0 1987 Vasopressin in end-stage renal disease: relationship to salt, catecholamines and renin activity. Catecholamines 62-76 arginine vasopressin Homo sapiens 0-11 3318505-9 1987 Circulating catecholamines influence the release of vasopressin by alpha- and beta-adrenergic pathways. Catecholamines 12-26 arginine vasopressin Homo sapiens 52-63 6543178-0 1984 Impact of neonatal catecholamine treatment on adult response to vasopressin and norepinephrine. Catecholamines 19-32 arginine vasopressin Homo sapiens 64-75 6543178-1 1984 The present experiments have shown that neonatal imprinting with certain catecholamines had a significant impact on adult vascular adrenergic response, and on adult response to vasopressin as well. Catecholamines 73-87 arginine vasopressin Homo sapiens 177-188 6511455-0 1984 Mechanism of suppression of pressor vasopressin secretion by circulating catecholamines. Catecholamines 73-87 arginine vasopressin Homo sapiens 36-47 6107928-6 1980 Regional studies by microdissection techniques in combination with a sensitive radioenzymatic catecholalmine assay, indicate that vasopressin modulates memory processes by modulation of neurotransmission in distinct catecholamine systems. Catecholamines 216-229 arginine vasopressin Homo sapiens 130-141 6324242-0 1984 Effects of catecholamine-related mammalian alkaloids on spontaneous and vasopressin-induced behavior in mice. Catecholamines 11-24 arginine vasopressin Homo sapiens 72-83 5637142-9 1968 These data support the hypothesis that catecholamine blocks the cellular mechanism of vasopressin antidiuresis in vivo. Catecholamines 39-52 arginine vasopressin Homo sapiens 86-97 170549-3 1975 A ROLE OF VASOPRESSIN IS IMPLICATED SINCE NEITHER MAN NOR DOG WITHOUT A PITUITARY SOURCE OF VASOPRESSIN DEMONSTRATE THE SAME EFFECT OF CATECHOLAMINES ON WATER EXCRETION AS OBSERVED IN INTACT MAN AND DOG. Catecholamines 135-149 arginine vasopressin Homo sapiens 10-21 13962157-0 1963 [Effect of vasopressin on adrenal catecholamine secretion]. Catecholamines 34-47 arginine vasopressin Homo sapiens 11-22 34017842-4 2021 Since the half-life of vasopressin is longer than that of catecholamines, we hypothesized that vasopressin loading may be effective for predicting responses to its continuous administration. Catecholamines 58-72 arginine vasopressin Homo sapiens 95-106 33981424-12 2021 Conclusions: Vasopressin could be an option for treating hypotension secondary to ARB and CCB toxicity when catecholamines and treatment for CCB toxicity fail. Catecholamines 108-122 arginine vasopressin Homo sapiens 13-24 33285135-8 2022 Patients with higher copeptin levels, underwent more complex procedures, had longer cardiopulmonary bypass times, required more catecholamine support, needed longer time of invasive ventilation, and had a longer overall stay and ICU stay. Catecholamines 128-141 arginine vasopressin Homo sapiens 21-29 32685251-1 2020 We report two cases of neonates with complex congenital heart disease and volume, catecholamine, and corticosteroid refractory shock treated with arginine-vasopressin. Catecholamines 82-95 arginine vasopressin Homo sapiens 155-166 31025531-2 2019 During the procedure, the patient developed catecholamine refractory hypotension requiring the administration of several vasopressin boluses to maintain adequate perfusion pressure. Catecholamines 44-57 arginine vasopressin Homo sapiens 121-132 29908046-8 2019 Vasopressin, angiotensin II, and, paradoxically, alpha2 -adrenergic receptor agonists (clonidine and dexmedetomidine) may be feasible adjunct therapies for catecholamine-resistant vasodilatory shock. Catecholamines 156-169 arginine vasopressin Homo sapiens 0-11 29801010-19 2018 Conclusions and Relevance: In this systematic review and meta-analysis, the addition of vasopressin to catecholamine vasopressors compared with catecholamines alone was associated with a lower risk of atrial fibrillation. Catecholamines 103-116 arginine vasopressin Homo sapiens 88-99 29569847-5 2018 Albumin, vasopressin and hydrocortisone have each been shown to support blood pressure and reduce catecholamine requirements but without effect on mortality, and as such should be considered for ED patients with septic shock on a case-by-case basis. Catecholamines 98-111 arginine vasopressin Homo sapiens 9-20 31797234-7 2020 Compared with catecholamine therapy alone, the addition of vasopressin or its analogues was associated with a reduced risk of mortality (relative risk [RR], 0.91; 95% confidence interval [CI], 0.85 to 0.99; low certainty), reduced risk of atrial fibrillation (RR, 0.77; 95% CI, 0.67 to 0.88; high certainty), and increased risk of digital ischemia (RR, 2.56; 95% CI, 1.24 to 5.25; moderate certainty). Catecholamines 14-27 arginine vasopressin Homo sapiens 59-70 31567344-1 2019 OBJECTIVES: Vasopressin has achieved common usage for the treatment of catecholamine-requiring and catecholamine-resistant shock. Catecholamines 71-84 arginine vasopressin Homo sapiens 12-23 31567344-1 2019 OBJECTIVES: Vasopressin has achieved common usage for the treatment of catecholamine-requiring and catecholamine-resistant shock. Catecholamines 99-112 arginine vasopressin Homo sapiens 12-23 30597665-7 2019 Physiologic replacement with exogenous Arginine vasopressin results in significant increases in systemic vascular resistance and mean arterial pressure with decreased requirements of catecholamines. Catecholamines 183-197 arginine vasopressin Homo sapiens 48-59 30597665-10 2019 Exogenous administration of low-dose Arginine vasopressin alone or in combination with traditional catecholamines is a safe and effective way to manage this type of vasodilatory shock. Catecholamines 99-113 arginine vasopressin Homo sapiens 46-57 29240642-4 2018 The association of weight- and BMI-adjusted vasopressin dose with change in catecholamine dose and change in mean arterial pressure (MAP) were evaluated using Spearman"s correlation. Catecholamines 76-89 arginine vasopressin Homo sapiens 44-55 29240642-9 2018 Comparable findings were observed when evaluating correlations between BMI-adjusted vasopressin dose with change in MAP and catecholamine dose at all time points (all P values >0.05). Catecholamines 124-137 arginine vasopressin Homo sapiens 84-95 29089189-1 2018 Vasopressin is a potent vasopressor used for improving organ perfusion during cardiac arrest, septic and catecholamine-resistant shock; with reference to this, it is useful for the treatment of vasoplegic shock because, restoring organ perfusion pressure by contraction of vascular smooth muscle through a non-catecholamine receptor pathway, it can be employed when catecholamines are ineffective. Catecholamines 105-118 arginine vasopressin Homo sapiens 0-11 29089189-1 2018 Vasopressin is a potent vasopressor used for improving organ perfusion during cardiac arrest, septic and catecholamine-resistant shock; with reference to this, it is useful for the treatment of vasoplegic shock because, restoring organ perfusion pressure by contraction of vascular smooth muscle through a non-catecholamine receptor pathway, it can be employed when catecholamines are ineffective. Catecholamines 366-380 arginine vasopressin Homo sapiens 0-11 29089189-4 2018 Only the vasopressin infusion, in association with catecholamines, gradually stabilized the patient"s hemodynamic status. Catecholamines 51-65 arginine vasopressin Homo sapiens 9-20